Quest Diagnostics/$DGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Quest Diagnostics
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Ticker
$DGX
Sector
Primary listing
NYSE
Employees
50,500
Headquarters
Website
DGX Metrics
BasicAdvanced
$20B
21.84
$8.35
0.49
$3.10
1.76%
Price and volume
Market cap
$20B
Beta
0.49
52-week high
$185.62
52-week low
$146.17
Average daily volume
732K
Dividend rate
$3.10
Financial strength
Current ratio
1.086
Quick ratio
0.859
Long term debt to equity
77.716
Total debt to equity
86.904
Dividend payout ratio (TTM)
36.00%
Interest coverage (TTM)
5.59%
Profitability
EBITDA (TTM)
2,052
Gross margin (TTM)
33.22%
Net profit margin (TTM)
9.03%
Operating margin (TTM)
14.40%
Effective tax rate (TTM)
22.35%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
6.34%
Return on equity (TTM)
14.26%
Valuation
Price to earnings (TTM)
21.836
Price to revenue (TTM)
1.931
Price to book
2.82
Price to tangible book (TTM)
-6.07
Price to free cash flow (TTM)
16.602
Free cash flow yield (TTM)
6.02%
Free cash flow per share (TTM)
10.978
Dividend yield (TTM)
1.70%
Forward dividend yield
1.76%
Growth
Revenue change (TTM)
12.58%
Earnings per share change (TTM)
12.66%
3-year revenue growth (CAGR)
-0.19%
10-year revenue growth (CAGR)
3.37%
3-year earnings per share growth (CAGR)
-11.56%
10-year earnings per share growth (CAGR)
9.35%
3-year dividend per share growth (CAGR)
6.59%
10-year dividend per share growth (CAGR)
8.12%
What the Analysts think about DGX
Analyst ratings (Buy, Hold, Sell) for Quest Diagnostics stock.
Bulls say / Bears say
Quest Diagnostics raised its full-year 2025 revenue guidance to $10.80 billion–$10.92 billion and adjusted EPS guidance to $9.63–$9.83 after a 15.2% Q2 revenue increase and 11.5% adjusted EPS growth, underscoring strong demand and execution (Reuters).
The March 2025 collaboration with Google Cloud to deploy generative AI across operations and customer service is expected to enhance data analytics, streamline workflows, and personalize patient experiences, driving productivity gains (FierceBiotech).
The acquisition of Fresenius Medical Care’s kidney dialysis testing portfolio will expand Quest’s end-stage kidney disease testing services and leverage its nationwide lab network to shorten result turnaround times (FierceBiotech).
Executives warned that ongoing tariffs introduced in Q2 are expected to persist through later quarters, potentially increasing operating costs and squeezing margins at Quest Diagnostics (Benzinga).
The Protecting Access to Medicare Act (PAMA) slated for January 2026 could cut Medicare payments by up to 15% on 800 laboratory services, projecting a $100 million impact on Quest’s earnings unless legislative reforms are passed (Investor’s Business Daily).
Organic requisition volume declined 0.9% year-over-year in Q1 2025 despite overall revenue growth, indicating underlying demand softness in core clinical testing services (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
DGX Financial Performance
Revenues and expenses
DGX Earnings Performance
Company profitability
DGX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Oct3
Quest Diagnostics
DividendEx-dividend
Oct20
Quest Diagnostics
DividendPayment
$0.80Per share
FAQs
What’s the current market cap for Quest Diagnostics stock?
Quest Diagnostics (DGX) has a market cap of $20B as of September 18, 2025.
What is the P/E ratio for Quest Diagnostics stock?
The price to earnings (P/E) ratio for Quest Diagnostics (DGX) stock is 21.84 as of September 18, 2025.
Does Quest Diagnostics stock pay dividends?
Yes, the Quest Diagnostics (DGX) stock pays dividends to shareholders. As of September 18, 2025, the dividend rate is $3.1 and the yield is 1.76%. Quest Diagnostics has a payout ratio of 36% on a trailing twelve-month basis.
When is the next Quest Diagnostics dividend payment date?
The next Quest Diagnostics (DGX) dividend payment is scheduled for October 20, 2025.
What is the beta indicator for Quest Diagnostics?
Quest Diagnostics (DGX) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.